Stockwinners Market Radar for June 02, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EDT Iovance Biotherapeutics director buys $6.6M in common stock - In a regulatory filing, Iovance Biotherapeutics disclosed that its director Wayne Rothbaum bought 1M shares of common stock on May 31st in a total transaction size of $6.6M.

19:47 EDT Frontier Airlines, Spirit Airlines announce amended merger agreement - Spirit Airlines (SAVE) and Frontier Group (ULCC), parent company of Frontier Airlines, Inc., "announced an amendment to their previously announced merger agreement dated February 5, 2022. Under the terms of the amended merger agreement, which has been unanimously approved by the boards of directors of both companies, Frontier would pay a reverse termination fee of $250M, or $2.23 per share, to Spirit in the unlikely event the combination is not consummated for antitrust reasons."

18:47 EDT Sony's PlayStation 'Spider-Man' games have sold over 33M copies globally - Sony's PlayStation unit said in a blog post that its PlayStation-exclusive "Spider-Man" franchise, which includes 2018's "Marvel's Spider-Man" and 2020's "Spider-Man: Miles Morales," has sold through more than 33M copies globally as of May 15, 2022. The company also announced that "Spider-Man Remastered" will be coming to PC on August 12, 2022, with a PC version of "Miles Morales" launching in Fall 2022. Reference Link

18:30 EDT Sony highlights VR titles, 'Final Fantasy XVI' at PlayStation event - At its State of Play event, Sony's (SONY) PlayStation unit made a number of announcements for PlayStation 5 and PlayStation VR 2, including: Capcom (CCOEY) announcing a March 24, 2023 release date for a remake of "Resident Evil 4" on PS5, as well as unveiling a PSVR2 version of "Resident Evil Village;" Capcom showing gameplay for "Street Fighter 6," out for PS4 and PS5 in 2023; "No Man's Sky" and "The Walking Dead: Saints & Sinners Retribution" coming to PSVR2, as well as more gameplay information on "Horizon: Call of the Mountain"; "Marvel's Spider-Man Remastered" coming to PC on August 12, 2022; and a new trailer for Square Enix's (SQNXF) "Final Fantasy XVI" was shown, with the game having a new release window of Summer 2023.

17:54 EDT Kohl's reverses losses, up over 6% to $43.77 after WSJ report on takeover bids

17:31 EDT Tenaris resolves SEC probe into legacy issue in Brazil - Tenaris (TS) has resolved a previously disclosed investigation by the U.S. Securities and Exchange Commission into allegations of improper payments between 2008 and 2013 to a manager of the Brazilian state-owned energy company Petroleo Brasileiro S.A. (PBR) for the benefit of Tenaris's Brazilian subsidiary Confab Industrial S.A. The U.S. Department of Justice has informed Tenaris that it has closed its parallel inquiry into this matter without taking action. Tenaris voluntarily notified the SEC and DOJ of this matter in 2016 and believes the resolution with the SEC is in the best interest of the company and its stakeholders. The company cooperated fully with investigators, as the SEC noted in its Order Instituting Proceedings. Under the settlement with the SEC, Tenaris neither admits nor denies the SEC's findings and will pay $53,100,338 in disgorgement and prejudgment interest and a $25,000,000 civil penalty to conclude the matter.

17:29 EDT SEC charges pipe-maker Tenaris $78M to resolve FCPA charges - The Securities and Exchange Commission announced that Tenaris (TS), a Luxembourg-based global manufacturer and supplier of steel pipe products, will pay more than $78M to resolve charges that it violated the Foreign Corrupt Practices Act, FCPA, in connection with a bribery scheme involving its Brazilian subsidiary. According to the SEC's order, the resolution with Tenaris is the result of an alleged bribe scheme involving agents and employees of its Brazilian subsidiary to obtain and retain business from the Brazil state-owned entity Petrobras (PBR). Specifically, the order finds that between 2008 and 2013, approximately $10.4M in bribes was paid to a Brazilian government official in connection with the bidding process at Petrobras. The bribes were funded on behalf of Tenaris' Brazilian subsidiary by companies affiliated with Tenaris' controlling shareholder...This is not the first time Tenaris has been involved in a corruption scheme. In 2011, the company entered into a Non-Prosecution Agreement with the Department of Justice and a Deferred Prosecution Agreement with the SEC as a result of alleged bribes the company paid to obtain business from a state-owned entity in Uzbekistan. Tenaris consented to the SEC's order without admitting or denying the findings that it violated the anti-bribery, books and records, and internal accounting controls provisions of the Securities Exchange Act of 1934 and agreed to pay more than $78M in combined disgorgement, prejudgment interest, and civil penalties. The company also agreed to comply with undertakings for a two-year period related to its ongoing remedial efforts. Reference Link

17:24 EDT Northrop Grumman awarded on $249.13M Missile Defense Agency contract - Northrop Grumman and Owl Cyber Defense were awarded competitive multiple-award, indefinite-delivery/indefinite-quantity firm-fixed price and cost-reimbursement contracts with a five-year ordering period ending on June 2. The ceiling value is $249.13M and will be shared across all contract awardees. Each awardee will be provided a fair opportunity to be considered for each order unless an exception applies. The Missile Defense Agency, or MDA, is the implementing agency for Foreign Military Sales, or FMS, Cross Domain Solutions, or CDS, for the Department of Defense. These contracts were competitively procured via publication on the SAM.gov website. FMS funds will be used to fund subsequent task and delivery orders. MDA has received FMS CDS cases with Qatar and Morocco for a FMS CDS solution. An amount of $10,000 will be obligated on two delivery orders for a contract kick off meeting to meet the contract minimum order requirement. The MDA is the contracting activity.

17:11 EDT Riot Blockchain says initiating project to refurbish fleet of S17-Pro Antminers - CEO Jason Les says: "During May, we continued to make progress on the ongoing expansion of our Whinstone Facility in Rockdale, TX. We're proud to report that our first immersion building, Building F, is filled with approximately 23,000 S19 series miners. Approximately 7,000 of those miners are staged in the immersion-cooling tanks and are anticipated to be deployed pending installation of the final requisite components. Once these miners and other staged miners are fully deployed, our hash rate capacity is expected to increase to 5.4 EH/s. Additionally, we are initiating a project to refurbish our fleet of S17-Pro Antminers to improve their overall hash rate and efficiency. These enhancements are made possible by the improved operating environment facilitated by our immersion-cooling technology. While undergoing the refurbishing process, our fully-depreciated fleet of 4,000 S17-Pro miners will be temporarily decommissioned. These 4,000 miners will no longer be counted in our deployed fleet figure, and their corresponding 225 PH/s of hash rate will no longer be counted in our hash rate capacity figure."

17:08 EDT Sphere 3D reports Q1 bitcoin production of 12.57 bitcoins - The company states: "From May 1, 2022, through May 31, 2022, Sphere 3D's mining operation produced 12.57 Bitcoin, or 0.41 Bitcoin daily. Production increased approximately two percent over the 12.35 coins produced in April 2022. The equivalent approximate valuation of the Company's production, based on a Bitcoin price of $31,792 on May 31, 2022, totaled $13,000 per day and $400,000 for the month. Since the Company began its mining operations during the first quarter of 2022, it has produced 43.07 coins and held 37.05 Bitcoin on May 31, 2022. This represented a valuation of about $1,180,000 based on the Bitcoin price of $31,792 on May 31, 2022." CEO Patricia Trompeter says: "Our primary focus is growing our mining operations. Our fleet of S19j Pros is producing as expected, and we are deploying our new miners as rapidly as possible. We are laser-focused on executing our strategy of becoming a leading carbon-neutral Bitcoin mining company. The executive team and Board of Directors continue to evaluate options for the long-term financing of our fleet. Current geopolitical and financial issues have delayed our efforts as banks and institutions grapple with the potential outcome of higher inflation and the uncertain economic outlook."

17:01 EDT StoneCo jumps 24% to $12.95 after Q1 results

16:38 EDT Sprague Resources to be acquired by Hartree for $19.00 per share - Sprague Resources announced that it has entered into a definitive agreement and plan of merger pursuant to which an affiliate of Hartree Partners will acquire all of the outstanding common units of Sprague not already owned by Hartree and its affiliates. The agreement follows the offer made by Hartree on January 11 to acquire the common units. The agreement provides for an all-cash transaction, whereby each holder of the common units will receive $19.00 per common unit owned, representing a 27.3% premium to the closing price of the common units on January 10 the day prior to Hartree's offer, and an 18.9% premium to the closing price of the common units as of June 1. The board of directors of Sprague Resources, the general partner of Sprague, delegated to a conflicts committee of the GP board, consisting solely of the GP board's three independent directors, the authority to review, evaluate, negotiate and approve the transaction on behalf of the GP board. The Sprague Conflicts Committee, after evaluating the transaction with its legal counsel and independent financial advisor, unanimously approved the Agreement and determined it to be in the best interests of Sprague and Sprague's unitholders unaffiliated with Hartree. Under Sprague's partnership agreement, the transaction is required to be approved by the holders of a majority of the outstanding common units. An affiliate of Hartree owns approximately 74.5% of the outstanding common units, and immediately following the execution of the Agreement, that affiliate of Hartree delivered to Sprague a written consent approving the transaction. As a result, the transaction has been approved by the limited partners of Sprague, and Sprague will not hold a meeting of its unitholders to approve the transaction. Sprague will distribute an information statement to its unitholders describing the terms and conditions of the transaction. Upon closing of the transaction, Sprague will be a wholly owned subsidiary of Hartree and Sprague's common units will cease to be publicly traded. The transaction is expected to close prior to the end of Q3 2022, subject to customary closing conditions.

16:35 EDT Saga Communications increases quarterly cash dividend to 20c per share - Saga Communications announced that its board of directors declared a quarterly cash dividend of 20c per share. This is an increase from the previous quarterly dividend of 16c per share. The dividend will be paid on July 1 to shareholders of record on June 13. The aggregate amount of the payment to be made in connection with the quarterly dividend will be approximately $1.2M. The quarterly cash dividend will be funded by cash on the company's balance sheet. Including this dividend, the company will have paid over $79M in dividends to shareholders since the first special dividend was paid in 2012.

16:31 EDT BT Brands acquires founder's stake in Bagger Dave's - BT Brands announced that it had acquired 11,095,085 common shares representing 41.4% of Bagger Dave's Burger Tavern, Inc. for $1,260,000, approximately $.114 per share. Prior to completing the purchase of shares from Michael Ansley, founder and CEO of Bagger Dave's, agreed to cancel all voting preferred shares. In addition, upon closing, the current Bagger Dave's directors, including Mr. Ansley, resigned from the company, and its Board of Directors and representatives of BT Brands are assuming those positions. Gary Copperud, BT Brands' Chief Executive Officer, said, "Our Bagger Dave's investment allows BT Brands to immediately expand in the casual dining market with six restaurants generating a positive cash flow. At one time, Bagger Dave's had operated a total of 26 locations; the remaining six units represent a solid core that has been refined over the years. In addition, the Company has approximately $1.9 million in cash available for opportunities. We are confident that both BT Brands and the remaining Bagger Dave's shareholders will benefit from the transaction." Michael Ansley added, "the involvement of BT Brands as a shareholder assuming an active role is a positive for Bagger Dave's shareholders as our management team has worked hard to position Bagger Dave's to pursue new opportunities and now is an appropriate time and this is the focus of BT Brands."

16:30 EDT Axon names Joshua Isner as COO, effective immediately - On May 26, Axon Enterprise promoted Joshua Isner to COO, effective immediately. Isner has been the company's Chief Revenue Officer since January 2018, and previously held a number of roles at the company since 2009. Luke Larson, the company's President, has begun a medical leave of absence due to a serious, treatable health issue that arose in recent weeks. Isner will assume Larson's responsibilities going forward.

16:29 EDT ClearPoint Neuro receives certification for MDSAP - ClearPoint Neuro announced the receipt of certification for the Medical Device Single Audit Program, or MDSAP. MDSAP allows the conduct of a single regulatory audit of a medical device manufacturer's quality management system to satisfy the requirements of multiple regulatory jurisdictions or authorities enabling appropriate regulatory oversight of medical device manufacturers' quality management systems while minimizing regulatory burden on the industry. The

16:25 EDT El Pollo Loco appoints Ira Fils as CFO - El Pollo Loco (LOCO) announced that Ira Fils has been appointed CFO of El Pollo Loco, effective June 27. Fils joins El Pollo Loco from The Habit Burger Grill, a division of YUM! Brands (YUM).

16:23 EDT Costco reports May sales of $18.23B, up 16.9% - Reports May comparable sales up 15.5%. Reports May e-commerce sales up 6.3%.

16:17 EDT Huntington Bancshares appoints Amit Dhingra as Enterprise Payments Director - Huntington Bancshares is creating a new enterprise payments organization to develop, coordinate and execute on its payments strategy and investment roadmap. Amit Dhingra has been named Enterprise Payments Director and will lead a team responsible for executing an end-to-end enterprise-wide payments strategy across Consumer and Business Payments, Commercial Payments and Treasury Management. Dhingra will drive growth in payments revenue streams as well as focus on digital and customer experience enhancements. Dhingra previously served as Huntington's retail payments and consumer lending director. Before Huntington, he served in a variety of strategy and transformation leadership roles at U.S. Bank and McKinsey & Company.

16:16 EDT CNO Financial names Brian Schneider as Chief Risk Officer - CNO Financial Group announced the appointment of Brian Schneider as vice president, enterprise risk management and chief risk officer, effective immediately. Schneider reports to Chief Actuary Karen DeToro, who had previously served as the company's chief risk officer since June 2020. Schneider joined CNO in 2021 as vice president, enterprise risk management. Before joining CNO, he served as director of ERM at CNA Insurance, where he was responsible for enterprise-level risk identification, assessment, monitoring, and reporting.

16:12 EDT ClearSign provides operational update for Q1 - ClearSign provided an update on operations for Q1. Operational highlights during and subsequent to Q1 include: closed an underwritten public offering of 4,186,000 shares of its common stock at $1.11 per share. The total offering included 546,000 shares issued. Gross proceeds to ClearSign from this offering were approximately $4,646,460 before expenses. ClearSign intends to use the net proceeds from the offering for working capital, research and development, marketing and sales, and general corporate purposes. The company was awarded a government grant with the Department of Energy to develop ultra-low NOx hydrogen burner technology which will enable the adoption of hydrogen fuel for industrial heating. Initial funding is approximately $250K and the project will last six months starting at the end of June. The company will be able to submit a follow-up proposal for a Phase 2 grant of up to $1.6M for a two-year duration. The company received an initial engineering order from a large independent national refiner to retrofit two process heaters for a total of twenty ClearSign Core burners in one of their California refineries. The company has moved to Tulsa for strategic and business development benefits. Additionally, the company has been awarded an incentive through the Oklahoma 21th Century Quality Jobs Act incentive program from the Oklahoma Department of Commerce. Cash and cash equivalents were approximately $6,667,000 on March 31.

16:08 EDT Lululemon reports Q1 SSS up 28% or up 29% on constant FX - Q1 Comparable store sales increased 24%. Direct to consumer net revenue increased 32%, or 33% on a constant dollar basis. Direct to consumer net revenue represented 45% of total net revenue compared to 44% for the first quarter of 2021.

16:02 EDT Cybin announces publication of article on psychedelic-assisted psychotherapy - Cybin is "pleased to announce the publication of a peer-reviewed article introducing EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. The article was published on June 2, 2022 in the peer-reviewed journal Frontiers in Psychology and is titled, "Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model." Written by EMBARK's co-creators, Bill Brennan, PhD and Alex Belser, PhD, Cybin's Chief Clinical Officer, the article provides a detailed overview of EMBARK to the academic and clinical communities."

13:11 EDT FDA warns on Illumina cybersecurity vulnerability in letter to HCPs - The U.S. Food and Drug Administration announced that it is informing laboratory personnel and health care providers about a cybersecurity vulnerability affecting software in the Illumina NextSeq 550Dx, the MiSeqDx, the NextSeq 500, NextSeq 550, MiSeq, iSeq, and MiniSeq, next generation sequencing instruments. Some of these instruments have a dual boot mode that allows a user to operate them in either clinical diagnostic mode or RUO mode. The cybersecurity vulnerability affects the Local Run Manager software and an unauthorized user could exploit the vulnerability, the FDA stated. Reference Link

12:02 EDT Block says working with Apple on 'Tap to Pay' for iPhone - Block's (SQ) Square announced that it is working with Apple (AAPL) to enable "Tap to Pay" on iPhone, Apple's contactless payment acceptance capability, within the Square Point of Sale app. "The new offering enables sellers of all sizes to seamlessly and securely accept in-person contactless payments with only an iPhone and Square's industry leading POS app. Ahead of publicly launching the service later this year, Square also announced an Early Access Program for Tap to Pay on iPhone, allowing select sellers to begin testing the new technology," Square said in a statement.

12:00 EDT Oaktree Acquisition Corp. II falls -10.5% - Oaktree Acquisition Corp. II is down -10.5%, or -$1.05 to $8.91.

12:00 EDT Pure Storage rises 19.0% - Pure Storage is up 19.0%, or $4.56 to $28.57.

12:00 EDT Avaya rises 29.2% - Avaya is up 29.2%, or $1.25 to $5.50.

11:13 EDT Wolfpack short ZoomInfo, questions 'legitimacy and legality' of practices - Wolfpack Research said it is short ZoomInfo in a new report in which the firm questions "the legitimacy and legality of ZI's (secret sauce) data acquisition practices." ZoomInfo is a SaaS provider that "would like investors to believe that the secret to its success is 'proprietary insights' gained from investments in AI, ML, and 'human-in-the-loop solutions'," but "the real secret sauce, according to a high-level former employee, is the CEO's college roommate, a real estate broker by trade, who created SGN Database," the firm claims in its report. In morning trading, ZoomInfo Technologies shares are up $1.93, or 5%, to $42.83. Reference Link

11:06 EDT Keysight test solutions selected by NTU Singapore for 6G technology - Keysight Technologies announced that the Centre for Disruptive Photonic Technologies in Singapore has selected the company's software-centric test and measurement solutions to advance 6G technology based on terahertz frequencies. The Centre chose Keysight's solutions to validate on-chip terahertz electronic-photonic devices such as transceivers. Located at Nanyang Technological University, Singapore, the centre leverages terahertz frequencies to develop a unique electronic-photonic hybrid approach. It can be used to design mobile devices capable of efficiently operating at data rates of up to several terabits per second.

11:05 EDT Stingray Group launches Stingray Advertising - Stingray Group announced that InStore Audio Network has been fully integrated into its offering following the acquisition in January, and the combined entity of the US and Canadian operations is now named Stingray Advertising. This forms the largest in-store audio advertising network in North America, reaching 140 million shoppers each week in over 20,000 grocery retailers, superstores, discount stores and pharmacies. Stingray Advertising delivers targeted audio messaging to shoppers in a captive media environment at the point-of-purchase. This cutting-edge integration focuses on leveraging new technology and giving retailers a way to monetize in-store audio while offering CPG and HBC brands a democratized marketing tool to reach shoppers with optimized OOH media.

11:03 EDT Bristol-Myers says Orencia improved survival in study in COVID-19 hospitalized - Bristol Myers Squibb announced topline results from the Phase 3 Accelerating COVID-19 Therapeutic Interventions and Vaccines, or ACTIV-1, Immune Modulators clinical trial, sponsored by the National Institutes of Health. The study evaluated the safety and efficacy of a single dose of immune modulators, including Orencia IV 10 mg/kg versus placebo when given with standard of care to determine if modulating the immune system's response could speed recovery and reduce death in adults hospitalized with moderate to severe COVID-19. Treatment with Orencia versus placebo displayed "a strong but not statistically significant" improvement in the primary endpoint of time to recovery as measured by day of hospital discharge. Analyses of the secondary endpoints, which included mortality and clinical status, demonstrated Orencia reduced participants' risk of death and improved their clinical status at 28 days after entering the study when compared with placebo. The risk of death was lower for participants who received Orencia at 11%, versus 15% for those who received placebo, and the odds of dying were 37.4% lower. The relative improvement in mortality was similar in both moderately and severely ill participants. People in the Orencia group had 34.2% better odds of clinical improvement than those in the placebo group. The safety profile of Orencia remained consistent, with no new safety signals reported in the study. "The full report on these data will be published in a peer-reviewed scientific journal. Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration," the company stated.

10:49 EDT Douglas Elliman appoints Rick Moeser as CEO, business development - Douglas Elliman Realty announced that Rick Moeser has joined the company as CEO of Business Development. Moeser will lead the brokerage's efforts to expand into new markets, recruit top agent talent and identify new business opportunities. Moeser joins the company from Christie's International Real Estate, where he served for 17 years as Executive Director. Moeser will be a member of the corporate executive team.

10:44 EDT TerrAscend debuts Cookies, Gage brands in New Jersey - TerrAscend announced that it will officially launch Cookies and Gage-branded cannabis products in the State of New Jersey, on Saturday, June 11th. These products will be available exclusively at The Apothecarium locations in Maplewood and Phillipsburg.

10:31 EDT Hyatt appoints Javier Aguila as group president, EAME - Hyatt Hotels Corporation announced a leadership change positioning Hyatt for continued strategic growth in the Europe, Africa & Middle East region. Javier Aguila has been appointed incoming group president EAME, following the planned retirement of Peter Fulton who looks back on a 39-year career at Hyatt. Aguila and Fulton will work together through a smooth and thoughtful transition and Aguila will officially assume the role in the next several months. Aguila is an internal successor, hailing from Apple Leisure Group, which Hyatt acquired in 2021. He most recently served as ALG's group president, AMResorts Europe and Global Strategy.

10:09 EDT Vertex, Crispr Therapeutics say late-breaking CTX001 abstract accepted for EHA - Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association, or EHA, Congress. Late-breaking abstract #LB2367 entitled "Efficacy and Safety of A Single Dose of CTX001 For Transfusion-Dependent undefinedeta-Thalassemia and Severe Sickle Cell Disease," will be an oral presentation on Sunday, June 12. The abstract from Vertex and CRISPR Therapeutics includes data on patients treated in CLIMB-111 and CLIMB-121 and followed in CLIMB-131 with CTX001, now known as exagamglogene autotemcel, or exa-cel. This abstract has been selected for the media briefing program and is therefore embargoed until Saturday, June 11. Vertex also announced three abstracts accepted for poster presentation at EHA.

10:00 EDT Callon Petroleum falls -8.0% - Callon Petroleum is down -8.0%, or -$4.99 to $57.47.

10:00 EDT C3.ai falls -13.7% - C3.ai is down -13.7%, or -$2.54 to $16.01.

10:00 EDT Chewy rises 15.2% - Chewy is up 15.2%, or $3.57 to $27.06.

09:57 EDT Driver Management nominates candidate for Republic First Bancorp board - Driver Management Company, a shareholder of Republic First Bancorp, issued a statement regarding its decision to nominate a candidate for election to the Company's Board of Directors at a court-ordered special meeting of shareholders to elect one director to fill an existing vacancy on the Board. Abbott Cooper, Driver's founder and managing member, commented: "Like many shareholders, we are concerned by the level of board dysfunction at Republic First Bancorp that has resulted in the court-ordered appointment of a custodian to oversee the Company, as well as a court-ordered Special Meeting to elect one director to fill the existing vacancy on the Board. It is clear to us that this unfortunate and unprecedented situation is due to the intransigence of Vernon Hill, the Company's Chief Executive Officer, and his irrational commitment to a failed business model. Accordingly, we have nominated Peter Bartholow - Texas Capital Bancshares' former Chief Financial Officer, Chief Operations Officer and board member - for election to Republic First Bancorp's Board at the Special Meeting. If elected, Mr. Bartholow will work tirelessly to restore investor confidence and to preserve and enhance shareholder value. We hope that following the court-ordered Special Meeting, Republic First Bancorp will promptly call and hold its 2022 Annual Meeting of Shareholders, so that shareholders have the opportunity to support substantial Board-level change at the Company. In the meantime, it is our view that the election of Mr. Bartholow at the Special Meeting is absolutely necessary in order to eliminate the unacceptable dysfunction that has rendered the Board incapable of acting in the best interests of shareholders."

09:47 EDT Ciena falls -8.3% - Ciena is down -8.3%, or -$4.25 to $47.10.

09:47 EDT C3.ai falls -17.5% - C3.ai is down -17.5%, or -$3.25 to $15.30.

09:47 EDT UiPath rises 11.0% - UiPath is up 11.0%, or $1.85 to $18.68.

09:42 EDT Zhangmen Education Inc (Class A ADS) trading halted, news pending

09:39 EDT JX Luxventure signs technology consulting agreement for Metaverse - JX Luxventure Limited announced that, on June 1, 2022, Jin Xuan Luxury Tourism Digital Technology Co., Ltd., a subsidiary of the company, entered into and executed a Technology Consulting Agreement with Tianjin City Wei Ka Technology Co., Ltd. Pursuant to the Agreement, JX Hainan will provide technology consulting services to Tianjin Wei Ka for entering into Metaverse by delivering a solution for an NFT based virtual human host to be used on live stream platforms.

09:35 EDT Immunic trading resumes

09:30 EDT Immunic trading halted, volatility trading pause

09:28 EDT Microsoft drops 2% to $265.70 after cutting Q4 outlook

09:23 EDT EPR Properties acquires Village Vacances Valcartier for $142M - EPR Properties announced that it is acquiring the Village Vacances Valcartier resort and hotel in Quebec City, Quebec, and the Calypso Waterpark in Ottawa, Ontario for aggregate consideration of approximately $142M using cash on hand. Simultaneous with the acquisition, the company is leasing these properties to Premier Parks pursuant to a long-term triple net lease. The Village Vacances Valcartier is an iconic four-season resort covering approximately 225 acres and offering indoor and outdoor water park attractions and winter activities, such as tubing and sledding, over 600 campground sites and a variety of food and beverage options. The resort also includes The Hotel Valcartier, a four-star modern hotel with 153 rooms, the Hotel de Glace which offers guests a unique winter experience and the Aroma Spa.

09:21 EDT Terreno Realty acquires $34.6M industrial property in California - Terreno Realty acquired an industrial property located in San Leandro, California on June 1 for a purchase price of approximately $34.6M. The property consists of five industrial distribution buildings containing approximately 104,000 square feet on 4.2 acres.

09:19 EDT Cosmos Holdings to launch Sky Premium Life supplements on Amazon - Cosmos Holdings announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, is launching Sky Premium Life products on Amazon in the United States. Cosmos expects to introduce fifteen Sky Premium Life SKUs in the third quarter of 2022, and targets having all 85 SKUs listed on Amazon by year end

09:18 EDT Jupiter Wellness appoints Paul Jones as senior project manager - Jupiter Wellness announced that Paul Jones has joined Jupiter Wellness as Senior Project Manager. .Most recently he was Project Manager in an Investment and Management Company with operations in South Florida and Italy. He was responsible for initiating projects in the US and Italy, managing costs, timelines, and project performance from initiation through completion.

09:16 EDT CareCloud announces results from annual shareholder meeting - CareCloud announced that it held its 2022 annual shareholders' meeting on June 1, 2022, during which shareholders re-elected A. Hadi Chaudhry, John N. Daly, Mahmud Haq, and Cameron P. Munter for another two-year term. Shareholders also voted to amend CareCloud's certificate of incorporation to increase the Company's authorized shares of common and preferred stock, as well as to amend CareCloud's Amended and Restated Equity Incentive Plan to add additional common and Series B preferred shares issuable under the plan. CareCloud's shareholders approved the following five proposals: Re-elect A. Hadi Chaudhry, John Daly, Mahmud Haq and Cameron Munter to the Board of Directors. Amend the Company's certificate of incorporation to increase the Company's authorized shares of common stock from twenty-nine million shares to thirty-five million shares. Amend the Company's certificate of incorporation to increase the Company's authorized shares of preferred stock from seven million shares to fifteen million shares. Amend the Company's Equity Plan to increase the number of shares of the Company's common stock issuable under the Equity Plan from 4,851,000 shares to 5,851,000 shares. Amend the Company's Equity Plan to add 200,000 shares of the Company's Series B Preferred Stock issuable under the Equity Plan.

09:15 EDT Global Ship Lease announces pricing of $350M senior secured notes due 2027 - Global Ship Lease announced that its indirect wholly-owned subsidiary, Knausen Holding, priced on June 1, 2022, an offering of $350 million aggregate principal amount of its 5.69% Senior Secured Notes due 2027 in a private placement to a limited number of accredited investors. The interest rate on the Notes was determined based on the 3.2 year Interpolated US Treasury Yield plus a spread of 2.85%. The Company intends to use the net proceeds from the private placement for the repayment of the remaining outstanding balance on its $236.2 million Senior Secured Loan Facility which bears interest at LIBOR plus a margin of 7.00%, and the remainder for general corporate purposes, which may include the repayment of other outstanding consolidated indebtedness of the Company. The issuance and sale of the Notes is expected to close on June 15, 2022, subject to customary closing conditions. Goldman Sachs & Co. LLC acted as Sole Structuring Agent and Lead Placement Agent. The Notes will be senior obligations of the Issuer, secured by first priority mortgages on 20 identified vessels owned by subsidiaries of the Issuer and certain other associated assets and contract rights, as well as share pledges over the Subsidiary Guarantors. In addition, the Notes will be fully and unconditionally guaranteed by GSL.

09:13 EDT Brilliant Earth opens 19th showroom, first location in Minnesota - Brilliant Earth Group announced the opening of its 19th showroom and first in the state of Minnesota. "We are thrilled to open our first showroom in Minnesota and bring our joyful in-store shopping experience to the larger Minneapolis community," said Kathryn Money, SVP of Merchandising and Retail Expansion, Brilliant Earth. "We were drawn to the location because we share 50th and France's vision of creating unique and curated shopping experiences for discerning customers in a comfortable and dynamic environment. We look forward to engaging with customers in the area and sharing our distinctive designs, personalized consultations, and jewelry customization process."

09:12 EDT Verizon MERIT team completes annual Hazardous Materials Recertification - With hurricane season here and wildfires affecting parts of the country, the Verizon MERIT team recently completed their annual Hazardous Materials Recertification training in Dallas.

09:10 EDT Elys Game Technology in pact with Petworth Wagering to operate a sportsbook - Elys Game Technology announced the agreement the Petworth Wagering to operate a sportsbook at Entitlement Restaurant and Cigar Lounge located at 829 Upshur Street NW, in Washington D.C. The Company's wholly owned subsidiary USBookmaking is expected to provide sport wagering and bookmaking services to manage the sportsbook risk. Entitlement is a full service neighborhood restaurant lounge situated in one of DC's trendiest communities in the Petworth district of Washington, DC. The venue serves traditional American food and an array of beverages in an inclusive environment designed for socializing and networking. If successfully licensed, Entitlement will become the fifth restaurant and bar in Washington, DC where patrons could enjoy the excitement of sports wagering on the Elys sportsbook system in the comfort and ambiance of their favorite social establishment. The agreement has an initial term of three years from the date of issuance of the license with two possible extensions of 2 years each. "We are looking forward to launching our fifth sportsbook with our latest partners and management team at Entitlement Restaurant and Cigar Lounge in the Petworth district of Washington, DC. and to further expanding our sportsbook footprint within restaurants and bars in DC and neighboring states over the coming months," commented Michele Ciavarella, Elys Executive Chairman. "We believe that adding sports wagering within an exciting environment where patrons can enjoy their favorite food and beverages could bring an entirely new vibe to the establishment and could drive ancillary revenue and foster employment opportunities for small businesses. Partnering with Entitlement provides further affirmation of the scalability and flexibility of the Elys retail sportsbook solution and is a key driver in our pathway to profitability and development of long-term shareholder value in Elys Game Technology.

09:10 EDT Kyndryl Holdings and Cisco partnering for enterprise management solutions - Kyndryl (KD) and Cisco (CSCO) announced a technology partnership to help enterprise customers accelerate their transformation into data-driven businesses powered by Cisco solutions and Kyndryl managed services. Kyndryl and Cisco will develop new private cloud services, network and edge computing solutions, software defined networking solutions and multi-network wide area network offerings that are delivered in an environment with advanced security capabilities. Under their partnership, Cisco and Kyndryl will focus on providing technologies, infrastructure expertise and managed services throughout a customer's entire cloud journey - starting with strategy and migration, through to running, maintaining, and supporting complex IT environments.

09:09 EDT Zoom Video hires Saxon as Chief People Officer - Zoom Video Communications (ZM) announced that Matthew Saxon will join the company as its Chief People Officer, effective immediately. Saxon brings more than 20 years of experience in human resources and people operations. He was most recently the Vice President of People Operations at Meta (FB).

09:08 EDT PharmaCyte Biotech announces $10M share repurchase program - PharmaCyte Biotech announced that its board of directors has authorized a share repurchase program to repurchase up to $10M of PharmaCyte's outstanding common stock. The share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash.

09:07 EDT Borqs Technologies completes $16M funding for growth of solar storage business - Borqs Technologies announced that it has received strategic funding of $16M for growth of its solar plus energy storage business in the markets outside of Hawaii particularly in California, and also for development of 5G mobile devices. The investment reflects the recognition of the Company's ESG strategy by the investors and will further strengthen and reinforce the Company's growth. The majority of this financing is led by TDR Capital Pty Limited, a private equity fund in Australia that focuses on emerging companies in various industries including solar. The funds raised will be used mainly for expansion of the Company's subsidiary, Holu Hou Energy business in mainland U.S., starting with California, including participation in power purchase agreements , which is the financing structure usually associated with multiple-unit residential solar solutions.

09:06 EDT Cardinal Health adds new distribution center in the Columbus Ohio area - Cardinal Health announced the addition of a new distribution center in the Columbus, Ohio, area as part of a multi-year warehouse modernization and growth plan. The new distribution center will support the company's at-Home Solutions business, a market-leading medical supplies provider and specialized business focused on providing comfortable care in the home for people with chronic and serious health conditions. Located in Grove City, the distribution center will create approximately 100 new job opportunities for the Ohio Valley market and is estimated to be fully operational in November, 2022.

09:05 EDT MoneyGram partners with Mobily Pay in Saudi Arabia - MoneyGram and Mobily Pay, a mobile wallet powered by Saudi-based telecommunications and digital service provider Mobily, announced a partnership to launch MoneyGram's international money transfer capabilities on Mobily Pay. The partnership is expected to be live for consumers later this year.

09:04 EDT Qualigen Therapeutics acquires majority stake in NanoSynex - Qualigen Therapeutics announces it has completed the acquisition of a majority stake in NanoSynex, an Israeli-based developer of next generation diagnostics technology. NanoSynex's award winning technology is an Antimicrobial Susceptibility Testing platform that aims to provide clinical laboratories worldwide with a rapid, accurate and personalized test for bacterial infections, especially difficult-to-treat drug resistant strains, with the goal of quickly matching the correct antibiotics at the correct concentration to treat a patient's specific infection. Michael Poirier, Qualigen's Chairman and CEO, commented, "Living through two and a half years of COVID-19 has taught us the critical role diagnostics plays in combating infectious disease, and the need to be prepared for the next wave. NanoSynex's technology shows great promise in rapidly and accurately matching antibiotics to the target bacteria, and in doing so, quickly equipping healthcare providers with the data needed to treat their patients with the right antibiotic at the right dose at the right time. We strongly believe in the potential of this platform, and our ability to leverage our long-standing diagnostics development, regulatory and commercial expertise to help bring the NanoSynex diagnostics technology to market sooner."

09:03 EDT Volaris reports preliminary May traffic up 12.3% - Volaris reports its May 2022 preliminary traffic results. In May 2022, Volaris' capacity increased 12.4% compared to May 2021, while demand increased 12.3% compared to the same period; the result was a load factor of 87.8%. Volaris transported 2.5M passengers during the month, a 17.5% increase compared to May 2021, as the company increased its fleet from 87 aircraft in May 2021 to 110 aircraft in May 2022. Passenger demand in the domestic Mexican and international markets increased 15.6% and 4.1%, respectively, compared to May 2021. Year-to-date, Volaris' demand increased 41.2% YoY, with a load factor expansion of 3.2 pp, to 84.6%. Commenting on May 2022 traffic figures, Volaris' President and CEO Enrique Beltranena said: "Demand remained strong in May, and Volaris demonstrated its ability to gradually pass through rising fuel prices. We continue growing with sustained traffic volume and improving TRASM."

09:02 EDT Ritchie Bros. names Eric Jacobs as CFO - Ritchie Bros. is pleased to announce that Eric Jacobs will be joining the company as its CFO, effective June 6. Sharon Driscoll, the company's current CFO, will remain with the company in an advisory capacity to assist with the transition prior to her previously announced retirement. Most recently, Jacobs served as CFO at Wheels Up Experience Inc., a marketplace for private aviation.

08:55 EDT NLS Pharmaceutics announces over enrollment in Phase 2a trial of Quilience - NLS Pharmaceutics announces that its Phase 2a clinical trial for Quilience in the treatment of narcolepsy is now fully enrolled, with top-line results anticipated to be presented at a symposium during the European Sleep Research Society Congress, being held September 27-30, 2022 in Athens, Greece. Additionally, the Company reports that enrollment and ongoing patient dosing in its OLE study for Quilience monotherapy continue to exhibit favorable trends.

08:55 EDT Intrusion enters reseller agreement with InnerCore Technologies - Intrusion announced a reseller agreement with InnerCore Technologies. InnerCore Technologies will resell Intrusion's products to its customer base of leading resorts and vacation destinations. Through this new reseller agreement with InnerCore Technologies, Intrusion has secured an important deal with a leading east-coast hospitality company. The agreement put in place with InnerCore Technologies, and its end-user, is a multi-year arrangement generating annual recurring revenue for Intrusion until at least 2025.

08:52 EDT Hillstream BioPharma sees sufficient capital for next 12 months - Hillstream BioPharma provided a corporate update for its investors and a roadmap of clinical studies through 2023. "We have demonstrated strong execution and as a result have seen significant advancement of our pipeline," said Randy Milby, Hillstream's Chief Executive Officer. "We received FDA Orphan Drug Designation for our lead drug candidate, HSB-1216, for the treatment of Uveal Melanoma, in addition to the Orphan Drug Designation for small-cell lung cancer. Our second drug candidate, HSB-888, also has the Orphan Drug Designation and a Rare Pediatric Disease Designation for pediatric osteosarcoma. We remain committed and laser-focused on our mission to improve the lives of patients suffering from rare, drug-resistant cancers. Looking forward, we have several important clinical milestones that we expect to achieve over the next 12 to 18 months. We are confident that our current financial capitalization levels will allow us to meet and exceed our expectations." The Company's lead drug candidate, HSB-1216, was granted Orphan Drug Designation to treat Uveal Melanoma by the FDA. The Orphan Drug Designation program provides orphan status to drugs and biologics, defined as those intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. For HSB-888, Hillstream's second product candidate is a Quatramer dual-loaded with an IMCD inducer coupled with our ultra-low-dose, next-generation anthracycline analog for solid tumors. HSB-888 has demonstrated highly synergistic tumor-killing capacity in a TNBC cell line. HSB-888's active moiety has also received FDA's Rare Pediatric Disease Designation and Orphan Drug Designation for pediatric osteosarcoma. The Company's growing and distinguished patent portfolio consists of 21 patents allowed and granted for polymeric nanoparticles with different active drugs, polymeric nanoparticles containing the active drug in HSB-1216, and the manufacturing process for polymeric nanoparticles. The current patent portfolio for those patents granted expires at the end of 2036. Additionally, there are approximately 25 patents that are still in pending status. As of the quarter ended March 31, 2022, Hillstream had $11.1 million in cash. The Company received total proceeds of $15 million through the issuance of common stock during its January 2022 initial public offering on the NASDAQ Exchange. The Company has sufficient capital to manage the business for the next 12 months. Notable Milestones Through 2023: For HSB-1216: Q4 2022: Initiation of GMP manufacture and Phase 0 study in Australia. 1H 2023: Completion of IND studies 2H 2023: Initiate Phase 1 clinical trial Moving forward, Hillstream expects to advance pre-clinical studies for other products, including HSB-888 and HSB-510.

08:49 EDT Conduent publishes 2021 corporate social responsibility report - Conduent published its 2021 Corporate Social Responsibility report, which highlights the company's continued progress in conducting business ethically, responsibly, and sustainably, while advancing its strategic Environmental, Social and Governance initiatives. Conduent's 2021 CSR report highlights our commitments and progress, including: Environmental - Protecting our planet; Reduced Scope 2 carbon emissions by 32% since 2019; Recycled 16 million pounds of paper in 2021; Recycled 36,700 electronic items in 2021; Reduced real estate square footage by 55% since 2017; Social - Supporting our people and communities; Allocated 25% of sourceable spending to diverse suppliers in the U.S.; Volunteered 2,372 hours in support of local communities; Recognized by Forbes as a Best Employer for Diversity; Recognized by Human Rights Campaign Foundation's Corporate Equality Index as Best Place to Work for LGBTQ+ Equality in the U.S. and Mexico; Social - Making a difference for millions through mission-critical solutions; Distributed $125 billion in payments to support government programs; Touched 75% of insured lives in the U.S. with Conduent Services; Processed approximately 3.3 billion tolling transactions; Managed 1.3 billion customer service interactions. Governance and Ethics - Responsibly governing our business; 87.5% of Conduent's Board of Directors are independent; 37.5% of Conduent's Board of Directors identify as female or ethnically diverse; 99% of Conduent's associates completed ethics training; Achieved ISO27001 corporate information security compliance; In 2021, the company expanded its ESG disclosures to include enhanced reporting aligned with the Task Force on Climate Related Financial Disclosures Governance and Strategy Recommendations. Conduent also continues its adherence to the Sustainability Accounting Standards Board framework, an independent standards-setting organization for sustainability disclosures, and remains aligned with five of the United Nations' Sustainable Development Goals that support its associates and their communities as well as its clients' end users: No Poverty; Zero Hunger; Good Health and Wellbeing; Sustainable Cities and Communities; Decent Work and Economic Growth.

08:47 EDT NXP Semiconductors board approves interim dividend of 84.5c per share - As part of its ongoing capital return program, NXP Semiconductors announced that its board of directors has approved the payment of an interim dividend. The actions are based on the continued and significant strength of the NXP capital structure, and the board's confidence in the company's ability to drive long-term growth and strong cash flow. The board of directors has approved the payment of an interim dividend of $0.845 per ordinary share for the second quarter of 2022. The interim dividend will be paid in cash on July 6, 2022 to shareholders of record as of June 15, 2022.

08:44 EDT Converge Technology to provide IBM Power Systems through Google Cloud - Converge Technology Solutions announced it will now provide IBM Power Systems through Google Cloud. Converge's IBM Power for Google Cloud Marketplace solution will also be generally available later this year in Frankfurt, Germany. This extended availability will help provide continuity of experience and feature parity with the Company's previously announced Google Cloud Marketplace solution, Converge Enterprise Cloud - IBM Power for Google Cloud, which currently operates in Google Cloud's US-East and US-Central cloud regions. IP4G allows Google Cloud clients to take advantage of enhanced infrastructure-as-a-service solutions centered around IBM Power Systems. IP4G supports clients on any Power operating system, including AIX, IBM i, or Linux on Power, and brings expanded capabilities and new geographic options for enterprise clients migrating to the cloud.

08:43 EDT Solid Biosciences reports inducement grant to SVP, Quality - Solid Biosciences announced the grant of inducement awards to its newly appointed Senior Vice President, Quality, Mark Tucker, PhD. The grant was approved by a majority of the independent directors of the Company on April 25, 2022 as an inducement material to Dr. Tucker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant to Dr. Tucker consisted of an option to purchase up to 120,000 shares of common stock and a restricted stock unit award with respect to 60,000 shares of common stock. The option has a ten-year term and an exercise price of $0.57 per share, the closing price per share of Solid Biosciences' common stock as reported by Nasdaq on June 1, 2022. The option and restricted stock unit award each vest in four equal installments on each one-year anniversary of Dr. Tucker's employment start date until the fourth anniversary of Dr. Tucker's start date, subject to Dr. Tucker's continued service with the Company through the applicable vesting dates

08:41 EDT Nano Dimension appoints Simon to board of directors - Nano Dimension announced the appointment of Saul Simon to the Board of Directors of the Company, effective immediately. Simon has decades of experience building automation platforms. Simon previously worked for Signals Analytics from 2013-2019.

08:39 EDT SLR Business Credit rebrands Fast Pay Partners to SLR Digital Finance - SLR Business Credit has announced that its subsidiary Fast Pay Partners has been rebranded as SLR Digital Finance. SLRDF provides asset-based loans and factoring facilities to ad tech and digital media businesses throughout the United States with borrowing needs ranging from $200,000 to $50 million. "This rebranding represents the SLR platform's commitment to providing bespoke financing solutions to middle market companies in the ad tech and digital media ecosystem," said Randy Mitzman, SLRDF's Senior Vice President/Managing Director. "The market in our vertical is rapidly changing, and, thanks to the creativity and collaboration nature of SLRDF and the SLR platform as a whole, we are at the forefront of financing innovative companies and technologies. I couldn't be more excited about our capabilities for financing ad tech and digital media businesses of all sizes and stages of growth."

08:38 EDT NLS Pharmaceutics announces overenrollment in Quilience trial for narcolepsy - NLS Pharmaceutics announces that its Phase 2a clinical trial for Quilience in the treatment of narcolepsy is now fully enrolled, with top-line results anticipated to be presented at a symposium during the European Sleep Research Society Congress ESRS, being held September 27-30, 2022 in Athens, Greece. Additionally, the Company reports that enrollment and ongoing patient dosing in its OLE study for Quilience monotherapy continue to exhibit favorable trends. "With patient enrollment now complete, we remain on track to report top-line efficacy and safety results from our Phase 2a narcolepsy trial for Quilience during the ESRS conference in late September," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "I believe that the over-enrollment of the trial demonstrates the high interest in our novel Mazindol ER formulation, as enrollment has significantly accelerated since we reported our positive interim results at the World Sleep Congress in March 2022. As we continue to execute on completing this trial, we are also continuing to work with our financial advisor to evaluate potential strategic partnerships and opportunities to bring Quilience to patients as quickly as possible."

08:38 EDT Eaton Partners launches Eaton Marketplace - Eaton Partners launched Eaton MarketPlace, an online community showcasing a variety of alternative investment opportunities currently being marketed by Eaton Partners. Eaton MarketPlace modernizes the fund placement process and empowers institutional investors to streamline how they uncover and evaluate potential private capital market investments. Eaton MarketPlace enables pre-qualified institutional investors to survey new investment opportunities and interact with Eaton representatives on their own timetable. Key features of Eaton MarketPlace include: Personalization: Users can filter and sort potential opportunities based on a variety of key investment criteria, including fund structure, strategy, and geography. Simplicity: Users have the ability to track mandates and receive updated fund materials and related documentation directly to their desktops or mobile devices. Quality: All funds on the platform have been thoroughly vetted by Eaton Partners.

08:37 EDT Assure streamlines operations, defers salaries for executive management - Assure Holdings announced the execution of strategic actions to make the business leaner and more profitable. These actions include the streamlining of operations and salary deferments for the executive management team which will prioritize resources for growth, accelerate the Company's path to profitability and create stakeholder value. The steps Assure is taking will reduce its monthly operating costs by greater than $200,000 per month. John Farlinger, Assure's executive chairman and CEO, said, "The Company is continuing to progress against our objective of performing 25,000 total managed cases for fiscal year 2022, a record number representing an increase of more than 40% compared with 2021 volume. In addition, Assure has maintained its strong cash collections pace since reporting record results in the first quarter of 2022. Given current capital market conditions, we have made the proactive decision to reduce our cost structure and accelerate becoming operating cash flow positive faster. We executed a similar strategy of cost containment during the much more severe COVID-19 related downturn in 2020, and I am confident that the actions we are implementing to streamline our operations, improve our processes and remove complexity and cost from our business will allow us to optimize our performance in these more challenging times. We believe we see a clear path to positive operating cash flow and profitability and are committed to achieving this objective on an accelerated timetable. In fact, Assure was operating cash flow positive in the month of May, and our goal is to generate positive operating cash flow results over the remainder of 2022."

08:35 EDT Ciena seeing 'a number' of positive demand trends - Comments taken from Q2 earnings conference call.

08:33 EDT Viracta Therapeutics' Phase 1b/2 trial of Nana-val advances to second dose - Viracta Therapeutics announced that the Safety Monitoring Committee for the ongoing Phase 1b/2 study of Nana-val in patients with EBV+ solid tumors has reviewed safety data from the first dose cohort of patients with recurrent or metastatic nasopharyngeal cancer and has approved advancing to the next dose level. Newly enrolled patients will enter the trial's second cohort and receive nanatinostat 30 mg orally, 4 days per week, in combination with valganciclovir 900 mg orally daily. Preliminary safety and efficacy data from the trial are expected in the second half of this year. In addition, the company also announced an upcoming poster presentation at the 2022 ASCO Annual Meeting, which will summarize the design of the Phase 1b/2 trial in patients with EBV+ RM-NPC and other EBV+ solid tumors. The Phase 1b/2 trial is an open-label, multinational trial evaluating Nana-val alone and in combination with pembrolizumab. The Phase 1b dose escalation portion is designed to evaluate safety and to determine the recommended Phase 2 dose of Nana-val in patients with EBV+ RM-NPC.

08:33 EDT MiMedx calls Prescience Point presentation 'highly misleading' - MiMedx Group addressed the "highly misleading" presentation published by Prescience Point on May 31, 2022. The company said, "Shareholders deserve the truth when considering any information published by Prescience Point: MIMEDX's executive compensation plan is directly aligned with shareholder value creation and pay levels are well within the average range in comparison with our peer group; The Compensation Committee worked with the entire Board to create a framework to transition the compensation program to align with where MIMEDX is today, implementing best practice pay-for-performance metrics consistent with industry expectations. Now that our management team has achieved the objective of putting MIMEDX on solid ground, our compensation program will focus more heavily on the performance of our growth strategy. Despite misstatements from Prescience Point, the fact is that NONE of the Company's executive officers received annual cash bonuses at their 2021 target levels, in part due to the decline in the Company's stock price. EW Healthcare is a substantial MIMEDX shareholder whose investment is directly linked to the performance of MIMEDX common stock, ensuring the alignment of its interests with those of all shareholders; MIMEDX's 2020 capital raise, conducted in the midst of the COVID-19 pandemic, was the culmination of an extensive review of potential financial alternatives by the Board of Directors, in consultation with the Company's professional and financial advisors. This strategic financing was prudent and beneficial to the Company and provided resources critical to stabilizing the business, prioritizing investments and pursuing attractive growth opportunities, signifying a clear turning point for the business. Despite Prescience Point's misleading statements, the truth is that when EW Healthcare and the Company entered into their non-binding term sheet for EW to invest in the Company, the conversion price of EW Healthcare's preferred stock was set at a premium to where MDXG shares were then trading. In fact, the conversion price was set at $3.85 per share, and the closing price that day was $3.47 per share. Today, EW only has TWO seats on the Board despite the firm's nearly 20% ownership stake in MIMEDX. Prescience Point falsely claims that Dr. Gardner is affiliated with EW, when in fact, she was identified as one of several Board candidates by a third-party executive search firm based on her strong independent credentials, significant operating expertise and decades of experience in medicine and healthcare. As Prescience Point is well aware, Dr. Gardner had no affiliation with EW Healthcare for nearly a decade at the time of her appointment. Despite the fact that Prescience Point has actively been selling down its interest in the Company and today owns less than 7% of MIMEDX's outstanding shares, Prescience Point has already nominated THREE directors to the Board. In addition, Prescience Point most recently demanded two additional Board seats, including the right to designate the Board Chair...MIMEDX has an established history of transparency and constructive shareholder engagement; MIMEDX communicates directly and regularly in a responsible, compliant and transparent manner regarding our results and prospects. In close to 350 meetings since our relisting in November 2020, we have kept investors informed about our pipeline potential in a timely and prudent manner, consistent with SEC and FDA guidelines. During the Company's December 2021 Investor Day, which attracted more than 445 attendees, we spent a significant amount of time on the AMNIOFIX/mdHACM opportunity as a potential blockbuster biologic; this included recent trial results, key findings, the Company's path forward, and possible variables in the Total Addressable Market for mdHACM. There are no shortcuts in this business, and we will continue to maintain an open dialogue with all our shareholders and solicit their constructive input as we move forward."

08:32 EDT Dave launches cash back rewards for all Dave Spending members - Dave announced the arrival of cash back rewards for all Dave Spending members with the launch of Dave Rewards. Dave is the banking app on a mission to create products that level the financial playing field. "Bringing top-tier debit card rewards to our members, who are not typically approved for rewards-based credit cards, is a great example of Dave leveling the financial playing field. With inflation reaching historic highs, every dollar counts for the many people living paycheck to paycheck. This is yet another way that Dave provides a superior banking experience for the everyday American," said Jason Wilk, CEO of Dave. The Dave Rewards launch also includes a limited time promotional offer with gas stations across the United States, whereby all Dave members using their Dave Debit Mastercard will receive 10% in cash back rewards on gas purchases.

08:29 EDT Atlas Air takes delivery of first of four new Boeing 747-8 freighters - Atlas Air, a subsidiary of Atlas Air Worldwide Holdings (AAWW), announced it has taken delivery of a Boeing 747-8 freighter, which will operate on behalf of its customer Cainiao, the logistics arm of Alibaba Group (BABA), as part of a previously announced long-term agreement. The aircraft will increase capacity on routes between China and the Americas. This aircraft is the first of four new 747-8 freighters that Atlas expects to receive from Boeing this year. The addition of this 747-8F expands service for Cainiao between China, the United States, Brazil and Chile aboard the most capable, technologically advanced and environmentally-friendly widebody freighter, providing 20% higher payload capacity and 16% lower fuel consumption than the very capable 747-400F. "These four new 747-8s allow us to offer our customers significant growth opportunities to capitalize on strong demand and deliver value on what we consider among the best and most versatile widebody freighters in the market," said Michael Steen, Executive Vice President and Chief Commercial Officer, Atlas Air Worldwide. "We are pleased that the first of our new 747s will be placed on a long-term basis with Cainiao, as they continue strengthening their presence as a global e-Commerce logistics leader, and we look forward to continue supporting their growth and expansion."

08:28 EDT Vectivbio announces first two patients dosed in Phase 2 STARGAZE study - VectivBio announced the first two patients have dosed in STARGAZE, a Phase 2 clinical trial evaluating apraglutide, a next-generation, long-acting GLP-2 analog, in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease, GvHD, a life-threatening condition that occurs when immune cells from the donor attack a recipient's healthy cells after an allogeneic hematopoietic stem cell transplant. "With the dosing of the first two patients in the STARGAZE Study, we are excited to begin evaluating apraglutide, our next generation GLP-2 analog, for treatment of acute GvHD. We believe apraglutide, which received orphan drug designation from the FDA for the prevention of acute GvHD, offers a potential first-in-class approach to treating aGvHD. We look forward to sharing interim data from STARGAZE in the first half of 2023," said Omar Khwaja, M.D., Ph.D., Chief Medical Officer of VectivBio. "This study further establishes the broad potential of our lead candidate in treating severe diseases of the gut, as aGvHD is the second clinical indication we are studying with apraglutide. We plan to continue exploring the potential of apraglutide across a range of GI and other conditions where GLP-2 plays a central role."

08:26 EDT Tilt Holdings enters partnership with cannabis brand Highsman - TILT Holdings announced a new manufacturing and distribution partnership with Highsman, a purpose-driven cannabis lifestyle brand founded by former NFL running back, Ricky Williams. Highsman launched in November 2021, aiming to inspire a community of athletes and sports fans. Positioned at the intersection of sports and cannabis, Highsman's product playbook includes: Pregame, a collection of energizing and attention-grabbing sativas; Halftime, a collection of balanced and restorative hybrids; and Postgame, a collection of restful and recovery-focused indicas. TILT will launch Highsman in both Massachusetts and Pennsylvania in early September to kick off the 2022 football season. The addition of Highsman to the growing team of TILT brand partners is the first to be centered on sports enthusiasts and everyday athletes. TILT will carry the Highsman brand in its retail stores and will offer it throughout Massachusetts and Pennsylvania via TILT's wholesale channels.

08:23 EDT Vita Coco introduces Coconut Juice in two flavors - Vita Coco announces Vita Coco Coconut Juice, the brand's first juice offering, is available June 2. Vita Coco Coconut Juice is available in two flavors - Original with Pulp, and Mango. "Coconut Juice propels us into a new category, while allowing us to bring the power of coconuts to new consumers," said Jane Prior, Chief Marketing Officer at The Vita Coco Company. "A sweeter canned option of our hydrating and nutritious coconut water expands our consumption occasions by offering refreshing, bold flavors that pack the biggest tastebud punch."

08:22 EDT SafeAI, Siemens, Obayashi collaborate for heavy vehicle fleet - SafeAI announced a collaboration with Siemens to create an autonomous, zero emission heavy vehicle fleet for Obayashi Corporation. SafeAI and Siemens will work with Obayashi Corporation to create smarter, safer, more sustainable and productive construction sites. SafeAI and Obayashi originally announced their partnership in October 2020, beginning with a pilot site in Cupertino, CA, USA. Together, the two companies set out to address common pain points across construction-including unsafe working conditions, labor shortages and rampant inefficiencies-with autonomous solutions. Since then, they have successfully tested and deployed an articulated autonomous dump truck to complete over 580 load-haul-dump cycles. SafeAI and Siemens signed an agreement in May 2021 to jointly work on retrofitting off-road heavy vehicles for autonomy, zero emission and connected applications, due to the increasing convergence of these three megatrends in vehicles. SafeAI brings its powerful, scalable AI-powered retrofit autonomy to the collaboration, while Siemens provides its industry-leading hardware and software capabilities in zero emission powertrains, and the necessary infrastructure to operate these vehicles. Earlier this year, a fleet of 300 construction trucks-ranging from 45 - 65 tons and operated by Obayashi Corporation-was identified to be retrofitted for autonomy and zero emission. In May 2022, the companies began retrofitting the first 45 ton vehicle, which is expected to be ready by the end of 2022. The collaboration will continue scaling across the entire fleet over a three year period.

08:19 EDT Biogen, Samsung Bioepis' BYOOVIZ launches in United States - Biogen and Samsung Bioepis announced that BYOOVIZ, a biosimilar referencing LUCENTIS has been launched in the United States. Healthcare provider engagement, promotional activity, collaborations with professional societies and patient advocacy groups have commenced and BYOOVIZ will be commercially available on July 1, 2022, through major distributors across the U.S. The list price will be $1,130 per single use vial to administer 0.5mg via intravitreal injection, which is 40% lower than the current list price of LUCENTIS. Neovascular AMD, although less common than dry AMD, is responsible for the majority of the severe vision loss or blindness associated with AMD.

08:17 EDT DLH Holdings wins renewal of National Institute of Health contract - DLH Holdings announced it has been awarded a contract to provide statistical, mathematical, and computational support for the National Institute of Environmental Health Sciences, NIEHS, research. DLH has held this contract since 1986. The contract includes a base period of one year with four one-year options, for a total value of approximately $13M. Under this award, DLH will provide statistical analysis, research support, software programing, and data visualization for NIEHS' Division of National Toxicology Program, DNTP, and Division of Intramural Research, DIR. Areas of focus include carcinogenesis, neurotoxicity, immunotoxicity, toxicology, and biology. "The strength of our customer relationship is a source of tremendous pride for DLH, and we are honored to continue our work alongside the world-class researchers at NIEHS," said Zach Parker, DLH President and CEO. "The DLH team will continue to employ innovative statistical approaches that keep step with emerging technologies and new scientific approaches to support the crucial public health work of NIEHS."

08:15 EDT Casa Systems powers YTL Communications 5G network with cloud-native 5G core - Casa Systems announced that YTL Communications Sdn Bhd has deployed Casa Systems' cloud-native Ayxom 5G Core solution powering its 5G network and accelerating digital transformation across Malaysia. YTL Communications is the first service provider to launch a next generation 5G network in Malaysia. Jerry Guo, Chief Executive Officer at Casa Systems said: "This is a start of an exciting journey for YTL Communications and Casa Systems. 5G opens a new world of innovative possibilities for YTL with faster connectivity speeds, ultra-low latency, and greater bandwidth to advance communities, transform industries and dramatically enhance day-to-day experiences for their customers. This also reinforces the very positive trajectory for Casa's Connected Cloud solutions in 2022 and our position as an industry leader in cloud-native software technology."

08:14 EDT FBI reports 2.34M NICS firearm background checks in May - The FBI reported that there were 2,340,383 firearm background checks initiated through the NICS system in May 2022. This compares to 3,222,105 checks in May 2021 and 2,728,802 checks in April 2022. Publicly traded companies in the gun and ammo space include Smith & Wesson Brands (SWBI), Sturm Ruger (RGR), Vista Outdoor (VSTO) and AMMO (POWW). Reference Link

08:13 EDT InMed Pharmaceuticals announces $5M registered direct, private offerings - InMed Pharmaceuticals announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4,079,256 of its common shares at a purchase price of $0.858 per sharein a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 5,827,506 common shares. The aggregate gross proceeds to the Company of both offerings are expected to be approximately $5 million. The offerings are expected to close on or about June 6, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offerings to continue pipeline development, advance commercial activities and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The unregistered investment options to be issued in the offerings will be exercisable immediately upon issuance at an exercise price of $0.74 per share and will expire six and one-half years from the date of issuance. The Company also has agreed that certain existing warrants to purchase up to an aggregate of 4,480,771 common shares of the Company that were previously issued to the investor, with exercise prices ranging from $2.848 to $5.11 per share and expiration dates ranging from July 2, 2026 to November 16, 2026, will be amended effective upon the closing of the registered direct offering so that the amended warrants will have a reduced exercise price of $0.74 per share, will not be exercisable until six months following the closing of the registered direct offering and will expire seven years following the closing of the registered direct offering.

08:13 EDT Bit Origin signs LOI to purchase 850 Bitcoin Miners for $6.375M - Bit Origin announced that the Company has entered into a Letter of Intent, LOI, with certain company to purchase 850 Antminer S19j Pro Bitcoin Miners, which are expected to ramp up the hash rate of the Company's miner fleet by over 85,000 TH/s. The anticipated purchase of miners will increase the Company's total Bitcoin miners to 5,228 units, producing approximately 501.2 PH/s when all miners are operating at full capacity, and it is expected to produce 63.45 BTCs per month when all miners are deployed. Pursuant to the LOI, the Company agrees to purchase 850 Antminer S19j pro Bitcoin Miners in an aggregate value of $6,375,000. Lucas Wang, Chairman and Chief Executive Officer of the Company, commented, "We are very pleased to propose another asset purchase following the previous proposed purchase announced on June 1, 2022, and to continue working toward our strategic approach to accumulating miner assets. As we keep accumulating more miner assets and staying ahead of innovation, we are eyeing to become a leading bitcoin mining company."

08:11 EDT Erasca announces trial to evaluate ERAS-007 - Erasca announced a trial to investigate the ERK1/2 inhibitor ERAS-007 in combination with a KRAS G12C inhibitor in KRAS G12C-driven non-small cell lung cancer, NSCLC, and colorectal cancer, CRC. "We look forward to ERAS-007 being evaluated in this trial, based in part on ERAS-007's ability in preclinical studies to robustly shut down oncogenic signaling," said Jonathan Lim, M.D., Erasca's chairman, CEO, and co-founder. "This trial not only helps to broaden the therapeutic development of ERAS-007, but also complements the patient subgroups within our ongoing HERKULES-2 and HERKULES-3 master protocols. Additionally, it may provide proof-of-concept data supporting the addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance with KRAS G12C inhibitors. We look forward to potentially partnering with the team to explore the therapeutic potential of this combination." A Phase 1b clinical proof-of-concept trial will evaluate ERAS-007 in combination with a KRAS G12C inhibitor in patients with NSCLC and CRC harboring a KRAS G12C mutation.

08:09 EDT Harsco spotlights environmental solutions on World Environment Day - In recognition of World Environment Day, Harsco Corporation announces its continued commitment to improving sustainability and protecting our environment through beneficial reuse. The company said, "The launch of SteelPhalt's carbon-negative asphalt product exemplifies Harsco Corporation's commitment to environmental solutions in 2022. SteelPhalt is a part of Harsco Corporation's Harsco Environmental division. SteelPhalt's asphalt products use 95 percent recycled steel slag along with bitumen. Conventional asphalt products use bitumen, an oil-based product with a significant carbon footprint, to bind the asphalt. However, the business recently launched a new product that is carbon negative. Called SteelSurf ECO+, the new product uses kraft lignin-based Lineo, which is a renewable bio-based substance, to replace a portion of bitumen as the product's binder. Lignin comes from trees and is supplied by GautamZenUK in collaboration with Stora Enso. SteelSurfECO+ is also produced at reduced mixing temperatures compared to traditional asphalt. This reduced mixing temperature means that the amount of energy required to manufacture the product is lower. Ultimately, SteelSurf ECO+ is a carbon-negative asphalt product that delivers customers the skid resistance and durability that they expect. The new ECO+ range of products helps further reduce an industry leading low carbon footprint product range, that was already more sustainable than traditional asphalt due to the beneficial reuse of steel slag."

08:08 EDT Pharma Foods International, Olink initiate strategic partnership in Japan - Olink Holding announced that Pharma Foods International in Japan has initiated a partnership to use Olink technology to accelerate protein analysis services targeting Japanese customers. Pharma Foods International, PFI, is developing pharmaceuticals, functional food, and cosmetics for the Japanese and global market. PFI's advanced technologies include "ALAgene", proprietary avian-derived humanized antibody production technology. With this new partnership, PFI will be the first company in Japan to offer services utilizing the Olink Signature Q100 platform.

08:07 EDT BigBear.ai names Josh Kinley chief corporate development officer - BigBear.ai announced that it has expanded its leadership team to better execute on its growth strategy. Effective June 13, current CFO Josh Kinley will take a new role as chief corporate development officer, and former Amazon executive Julie Peffer will become CFO of the company. Peffer joins BigBear.ai from MedeAnalytics, a healthcare analytics company, where she served as CFO since January. As the company's first chief corporate development officer, Josh Kinley will drive strategic growth initiatives across the company's federal and commercial businesses, identifying and evaluating opportunities for Mergers and Acquisitions and leading integration strategy and execution.

08:06 EDT Boxed added to the MSCI Global Small Cap Indexes - MSCI USA Index - Boxed announced that the Company's stock was added to the MSCI Global Small Cap Indexes - MSCI USA Index, effective as of market close on May 31, 2022.

08:05 EDT PDS Biotechnology granted Fast Track Designation from FDA for PDS0101 - PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA. PDS0101 in combination with KEYTRUDA is being studied in the VERSATILE-002 Phase 2, open-label, multicenter trial for the treatment of recurrent or metastatic HPV16-positive head and neck cancer in collaboration with Merck (MRK). "We are thrilled that the FDA has granted Fast Track designation for PDS0101 in combination with KEYTRUDA," said Frank Bedu-Addo, Ph.D., Chief Executive Officer of PDS Biotech. "The HPV-associated head and neck cancer prevalence continues to rise, leaving this affected group with limited treatment options to date. Receiving this designation underscores the potential of the Versamune platform and the need for a new therapy that may improve outcomes for those with this devastating disease."

08:03 EDT DXC Technology awarded multiyear IT modernization contract by DIRECTV - DXC Technology has been awarded a multiyear contract to enhance and modernize mission-critical IT systems for video entertainment provider DIRECTV. DXC will deliver IT outsourcing services to enhance program management and modernize DIRECTV's infrastructure. The agreement is part of the major expansion of a customer relationship that has spanned more than 25 years. DXC will also provide risk management solutions, testing, storage and backup services.

08:02 EDT Zosano Pharma files voluntary petition for relief under Chapter 11 - Zosano Pharma announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware, thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a "debtor-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. Zosano is seeking approval of a variety of "first day" motions containing customary relief intended to enable the company to continue its ordinary course operations and to facilitate an orderly wind down of its operations. The company intends to sell substantially all of its assets during the bankruptcy case.

07:51 EDT Clearmind files provisional patent application related to cocaine addiction - Clearmind Medicine (CMNDF) announced it has filed a provisional patent application related to cocaine addiction.The move results from the company's recently launched collaboration with SciSparc (SPRC). The patent application refers to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide. The two companies plan to pursue a pre-clinical trial to examine the effect of the combination treatment as an anti-reward agent for treating cocaine addiction.

07:49 EDT Goldman Sachs sees medium-term ROE 14%-16%, ROTE 15%-17% - Sees medium-term efficiency ratio about 60%.

07:41 EDT OverActive Media, Bell announce multiyear extension of partnership - OverActive Media (OAMCF) and Bell (BCE) announced the renewal and expansion of their partnership, first established in 2019, for an additional three years. The multi-year extension further connects Bell to esports fans and reinforces its engagement with the gaming community in Canada. In addition to providing gamers with the fastest Internet technology, Bell is levelling up its esports investment alongside OverActive in the following ways: Bell acting as presenting partner of OverActive's largescale esports events including Toronto Ultra Major III this month and the Toronto Defiant Summer Showdown in September. The Bell Fibe Zone, a top-tier professional esports practice facility within OverActive's Toronto-based headquarters that is fully powered by Bell pure fibre Internet. Producing branded content, including OverActive's top-performing series "Bell presents The Blueprint," which provides a behind-the-scenes look at Toronto Ultra as they experience the trials and tribulations of the Call of Duty League season. Jersey and broadcast branding integration for both Toronto Ultra and Toronto Defiant.

07:40 EDT Real Brands signs LOI to acquire assets of Boulder Botanical - Real Brands announced that it has signed a letter of intent, LOI, to acquire substantially all the assets of Boulder Botanicals & Biosciences Laboratories, a manufacturer of white-label and private-label CBD and non-CBD products. The acquisition will include Boulder Botanical's brands, IP, distribution and 27,000 sq. ft. R&D and production facility in Golden, Colorado. On April 22, 2022, Boulder Botanical became a subsidiary of Frankens Investment Fund, LLC. This proposed transaction remains subject to a definitive agreement and due diligence. A formal closing is expected within the next few weeks. "The Boulder Botanical's transaction will augment Real Brands' existing portfolio of branded products and expand its distribution capabilities," explained Thom Kidrin, President & CEO of Real Brands Inc. "This deal will bring 150 proprietary formulations to Real Brands, and the R&D capabilities to create hundreds more. In addition, it should enlarge Real Brands' distribution channels as we shift from primarily online sales via Real Brands' own website and small, regionalized distributors to an existing national network with ready access to millions of potential consumers."

07:36 EDT Accuray partners with Limbus AI for radiotherapy solutions - Accuray and Limbus AI are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus' artificial intelligence-driven autocontouring algorithms, enabling automated contouring to further streamline the treatment planning process. The companies expect an integrated offering to be made available beginning in 2023. Automating the contouring portion of the overall planning process opens the door to practical adaptive plan modification, when warranted, for any patient undergoing treatment, without overwhelming already stretched clinical staff.

07:34 EDT Sanofi grants Regeneron worldwide exclusive license rights to Libtayo - Sanofi (SNY) restructures its immuno-oncology collaboration with Regeneron Pharmaceuticals (REGN). Under the amended and restated license and collaboration agreement, Regeneron will obtain worldwide exclusive license rights to Libtayo. Prior to today, the companies had split Libtayo's worldwide operating profits equally and co-commercialized Libtayo in the U.S., with Sanofi solely responsible for commercialization in the rest of the world. Under the terms of the amended and restated immuno-oncology license and collaboration agreement, Sanofi will transfer the rights to develop, commercialize, and manufacture Libtayo entirely to Regeneron, on a worldwide basis, over the course of a defined transition period. In exchange, Sanofi will receive an upfront payment of $900M, and an 11% royalty on worldwide net sales of Libtayo. Sanofi will also be entitled to a $100M regulatory milestone payment upon the first approval by either the FDA or European Commission of Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC, as well as sales-related milestone payments of up to $100M in total over the next two years. The transaction is subject to clearance under competition law and is expected to close in the third quarter of 2022. Regeneron will also accelerate reimbursement of the development balance associated with Regeneron and Sanofi's separate Antibody Collaboration. Regeneron will increase from 10% to 20% the share of its profits that are paid to Sanofi to reimburse Sanofi-funded development expenses, until Regeneron's share of the total cumulative development costs incurred under the collaboration has been reached.

07:34 EDT CME Group reached ADV of 24.3M contracts in May - CME Group reported its May 2022 market statistics, showing average daily volume increased 18% to 24.3M contracts during the month.

07:33 EDT Regeneron plans to buy Sanofi's stake in collaboration on Libtayo - Regeneron Pharmaceuticals (REGN) announced its intent to purchase Sanofi's (SNY) stake in the Regeneron and Sanofi collaboration on Libtayo, providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine. The transaction is subject to merger control clearance outside the United States and is expected to close in the third quarter of 2022. Once the transaction has closed, Regeneron will record 100% of global net sales and expenses for the Libtayo program. Libtayo, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells. It is currently approved by regulatory authorities in more than two dozen countries, including by the U.S. FDA as cemiplimab-rwlc monotherapy treatment for certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. Libtayo is a leading and first-in-class PD-1 inhibitor for the treatment of approved non-melanoma skin cancers and is considered a standard of care. Regulatory reviews are also underway for Libtayo in combination with chemotherapy as a first-line treatment in advanced NSCLC in multiple markets, including the U.S. and European Union, where approvals would provide promising opportunities to extend the medicine's reach. It is also currently being studied with 18 investigational agents in 22 clinical trials for a variety of difficult-to-treat cancers. These combinations include numerous assets from Regeneron, including its antibody targeting the LAG-3 checkpoint receptor, and several assets from its collaborators. Under the terms announced today, Sanofi will transfer the rights to develop, commercialize and manufacture Libtayo entirely to Regeneron, on a worldwide basis, over the course of a defined transition period. Upon closing of the transaction, Regeneron will make an upfront payment of $900M to Sanofi, which will be entitled to receive an 11% royalty on worldwide net sales of Libtayo. Sanofi will also be entitled to a $100M regulatory milestone payment upon the first approval by either the FDA or European Commission of Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC, as well as sales-related milestone payments of up to $100M in total over the next two years. Pursuant to the agreement, Regeneron will accelerate reimbursement of the development balance associated with Regeneron and Sanofi's separate Antibody Collaboration. Regeneron will increase from 10% to 20% the share of its profits that are paid to Sanofi to reimburse Sanofi-funded development expenses, until Regeneron's share of the total cumulative development costs incurred under the collaboration has been reached. Updates to 2022 GAAP and non-GAAP financial guidance as a result of this transaction will be provided following its successful completion. Assuming a third quarter 2022 close, there will be no financial or accounting impact to second quarter 2022 results.

07:29 EDT Ranger Oil's borrowing base increases by 20% - Ranger Oil Corporation announced that its borrowing base under its revolving credit facility was increased 20% to $875 million. Ranger's elected commitment under the facility remains at $400 million. This is the second announced increase this year for a total of approximately 45%. Darrin Henke, President and CEO said, "Ranger sits in an enviable position today with a strong capital structure, deep inventory of high-return opportunities, significant free cash flow and ample liquidity to execute our business plan through-cycle. This combination was recognized by our banking syndicate partners, as well as S&P Global with their upgrade on our Company credit rating to 'B'/stable outlook last week. Due to expected acceleration in second half production and growing free cash flow, we elected to keep our credit facility commitment at $400 million. Ranger's increased borrowing base provides meaningful scale and financial flexibility as we continue to evaluate accretive consolidation opportunities to add to our core Eagle Ford position."

07:23 EDT Telus receives approval for renewal of normal course issuer bid - TELUS Corporation has received approval from the Toronto Stock Exchange for a new normal course issuer bid to purchase and cancel, when and if considered advisable, up to C$250 million in shares over the 12 months commencing on June 6, 2022. The 2022 NCIB will permit the purchase of up to 10 million TELUS shares for an aggregate purchase price of up to C$250 million from June 6, 2022 to June 5, 2023 through the facilities of the TSX, the New York Stock Exchange and alternative Canadian trading systems or as otherwise permitted by applicable securities laws. The maximum number of shares that can be purchased during the same trading day on the TSX is 715,299 shares, subject to certain exceptions for block purchases. As of May 30, 2022, TELUS had 1,380,852,865 shares issued and outstanding. Shares purchased through the facilities of the TSX, NYSE or alternative Canadian trading systems will be purchased at market price. TELUS may also purchase shares privately pursuant to exemption orders from applicable securities regulatory authorities, and such purchases will generally be at a discount to the prevailing market price. Our 2021 NCIB, for which we had received approval to purchase up to 16 million shares for an aggregate purchase price of up to C$250 million, will conclude on June 3, 2022. TELUS did not purchase any shares pursuant to its 2021 NCIB. TELUS may enter into automatic share purchase plans with a broker to permit TELUS to purchase shares under its 2022 NCIB during internal blackout periods. Such purchases would be at the discretion of the broker based on prearranged parameters. Subject to TSX approval, the ASPP may be implemented on July 4, 2022, and from time to time thereafter. TELUS' Board of Directors believes that any purchases made under the 2022 NCIB will be in the best interest of TELUS and that such purchases will constitute an attractive investment opportunity that should enhance the value of the remaining shares.

07:18 EDT Renalytix announces two data presentations on KidneyIntelX - Renalytix announced its participation at the American Diabetes Association, ADA, 82nd Scientific Sessions meeting in New Orleans from June 3-7, 2022. There will be two data presentations focused on the value of KidneyIntelX in care for adult patients with type 2 diabetes, T2D, and early-stage chronic kidney disease, CKD, including a late-breaking ePoster and an oral presentation. The ePoster, "Clinical Utility of KidneyIntelX on Patients with Early-Stage Diabetic Kidney Disease-A Real-World Evidence Study" will be the first time Mount Sinai Health System is presenting data from its real-world evidence clinical utility study with Renalytix in 1,112 patients tested with KidneyIntelX. A second oral presentation, "KidneyIntelX Association with Clinical Outcomes in Diabetic Kidney Disease" will be on June 3.

07:17 EDT SpartanNash provides FY25 new long-term financial targets - On May 12, the Company also provided new long-term financial targets it expects to achieve by 2025. These included growing: Net sales to more than $10 billion, an increase of at least 12% from net sales in fiscal 2021. Adjusted EBITDA to more than $300 million, an increase of at least 40% from adjusted EBITDA in fiscal 2021. Adjusted EBITDA margin to 3% of net sales, an increase of 25% from adjusted EBITDA margin in fiscal 2021.

07:16 EDT Green Thumb Industries opens Good Green Grant applications - Green Thumb Industries opened applications for the third round of its Good Green Grant Program. First launched in the fall of 2021, Good Green offers affordable mixed bud flower products. Sales from Good Green products fund grants awarded to nonprofit organizations that give back to communities of color disproportionately affected by the War on Drugs. Since the brand's launch, Good Green has awarded more than $500,000 in grant money to eight organizations who encompass the brand's three core pillars: education, employment and expungement. Good Green is on track to give more than $1 million by the end of year.

07:13 EDT Tonix regains compliance with Nasdaq minimum bid price requirement - Tonix Pharmaceuticals announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On June 1, 2022, Tonix received a letter from The Nasdaq Stock Market stating that because Tonix's shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, Tonix's stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.

07:11 EDT Land's End drops 10% to $10.07 after Q2, FY22 guidance misses estimates

07:10 EDT Moog announces distributor agreement with Robin Radar Systems - Moog announced the formalization of its relationship with Robin Radar Systems, through the inclusion of Robin's Max and Iris radars into Moog's Digital Airfield Solutions portfolio. Moog customers will benefit through the integration of Robin's bird and drone detection systems into Moog's existing Tarsier FOD mitigation and pavement monitoring technologies. By bringing these normally siloed airfield systems together into one digital system, Moog can provide data insights to support the operators of airfield environments to optimize their FOD, pavement, wildlife, and drone management programs.

07:09 EDT Amesite says continuing 'to secure meaningful contract wins' - Amesite issued an update to its shareholders from its CEO Dr. Ann Marie Sastry and will be posting a video shareholder update to its website at 5:00 PM ET. The update read in part, "We believe that we have now entered a period of certainty in the need for expansion of online learning, contextualized by industrial disruption, rapid technology changes and obvious needs for workforce upskilling. Online learning was necessarily the default over two years of a pandemic, and we see signs that a shift in thinking has been permanent: the pandemic made clear the benefits and deficiencies of online experiences, and these have driven the desire to do better. We believe that reaching broader audiences through online learning, and importantly, making sure that all organizations that offer it can be effective, are essential. Our point of view is that the world's learning will not be delivered by a single organization, or even a few elite ones: learning is a fundamental human need. Just as dining at different restaurants stimulate the palate and the imagination, we believe that accessing learning from multiple channels is a desired human state. Amesite aims to serve this broad group - universities, museums, businesses and government - with outstanding, white label learning software, adaptable to their needs and true to their brands. Amesite continues to onboard customers in different sectors and grow relationships with existing partners to meet these needs. Despite a challenging economic macroenvironment, Amesite is building partnerships and revenue, by delivering solutions that these different organizations need to be successful in learning markets. We are positioning ourselves to be a leading educational platform service provider, by meeting common needs across sectors. Amesite has continued to secure meaningful contract wins and that momentum has continued into the current quarter. ..Our FYQ3 quarterly cash burn declined to $1.35 million, a 13.5% decrease from the same quarter in FY2021 and the lowest burn rate since our initial public offering. The most recent quarter was not an anomaly as our quarterly average burn was down 28.4% compared to the quarterly average year-to-date cash burn. Specifically, we completed a necessary 23% reduction in full-time from Q2 to Q3. Additionally, we offboarded contract IT, useful in the building phase of our product, and have moved development to our high performance, in-house team. Exiting this vendor resulted in an immediate termination payment of roughly $300,000 that was recognized in FYQ3 with expected costs savings to be realized going forward. Conversely, we reduced in-house marketing staffing in favor of external firms, with resulting increases in generation of marketing qualified leads and reduced payroll cost. Ultimately, what we think differentiates Amesite and drives both our past and future growth opportunity is our highly customizable, easy-to-deploy and operationally efficient SaaS platform. We invested significant time and effort to develop the supporting architecture specifically for the online business, university, institute / museum and government education markets, and we are very proud to be making inroads within those markets, as referenced above."

07:08 EDT Origin Materials gets USDA Certified Biobased Product label for more products - Origin Materials announced that it has earned the U.S. Department of Agriculture, or USDA, Certified Biobased Product label for multiple additional products. The certification affirms that Origin's furandicarboxylic acid, purified terephthalic acid and para-xylene, when produced at full commercial capacity, are expected to be 100% biobased, allowing Origin to display a unique USDA label highlighting this designation.

07:06 EDT Pintec Technology regains Nasdaq compliance - Pintec Technology announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

07:05 EDT LumiraDx announces CE Mark for new NT-proBNP test - LumiraDx announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism, or VTE, in symptomatic patients. With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care.

07:05 EDT Axsome Therapeutics presents new data from GEMINI trial on AXS-05 - Axsome Therapeutics announced that treatment with AXS-05 rapidly and significantly reduced anhedonic symptoms in the GEMINI Phase 3 trial in major depressive disorder, MDD. These new data are being presented today at the American Society of Clinical Psychopharmacology, ASCP, 2022 Annual Meeting, being held in Scottsdale, Arizona and virtually. The GEMINI trial assessed the efficacy and safety of AXS-05 versus placebo in patients with MDD. A total of 327 patients with a confirmed diagnosis of moderate to severe MDD were randomized to receive AXS-05, or placebo, once daily for the first 3 days and twice daily thereafter, for a total of 6 weeks. The primary endpoint was the treatment effect on the Montgomery-Asberg Depression Rating Scale score from baseline to week 6. In this secondary, post-hoc, analysis of the trial, improvements in anhedonic symptoms in MDD were assessed by the MADRS anhedonia subscale. In the trial, AXS-05 demonstrated rapid, substantial, and statistically significant improvement in symptoms of anhedonia compared with placebo. The change from baseline to week 6 on the MADRS anhedonia subscale was significantly greater with AXS-05 than with placebo. The improvement was rapid with the change on the MADRS anhedonia subscale from baseline to week 1, the first timepoint assessed, being significantly greater with AXS-05 than with placebo. Response, defined as at least a 50% improvement on the anhedonia subscale, was achieved by a statistically significantly greater proportion of patients treated with AXS-05 than with placebo at week 1 and at every timepoint thereafter. At week 6, response on the anhedonia subscale was achieved by 54% of patients treated with AXS-05 compared to 36% of patients treated with placebo.

07:04 EDT Bausch + Lomb announces U.S. launch of Biotrue Hydration Plus Solution - Bausch + Lomb announced the U.S. launch of Biotrue Hydration Plus Multi-Purpose Solution. The new contact lens solution, which is formulated with bio-inspired ingredients, provides more moisture on lenses, excellent cleaning and a triple disinfectant system that helps deliver exceptional disinfection.

07:02 EDT Palantir granted expanded contract award with U.S. Space Systems Command - Palantir announced that the U.S. Space Systems Command Battle Management Command, Control, and Communications awarded Palantir a $53,899,333.40 increase on May 24 to its 2021 award of $121.5M. This increase brings the total value of the contract to $175,399,333.40 and ensures the continuous delivery of Palantir's data and decisions platform to support national security objectives through March 2023. This contract modification continues Palantir's Data-as-a-Service platform capabilities. The extension includes capabilities for decision support tooling for echelon planning and continuity of leadership operations.

06:52 EDT The Buckle reports May net sales up 5.1% year-over-year - The Buckle reported comparable store net sales, for stores open at least one year, for the 4-week period ended May 28, 2022, increased 5.3% from comparable store net sales for the 4-week period ended May 29, 2021. Net sales for the 4-week fiscal month ended May 28, 2022 increased 5.1% to $94.3M from net sales of $89.7M for the prior year 4-week fiscal month ended May 29, 2021. Comparable store net sales year-to-date for the 17-week period ended May 28, 2022 increased 4.1% from comparable store net sales for the 17-week period ended May 29, 2021. Net sales for the 17-week fiscal period ended May 28, 2022 increased 3.7% to $403.4M vs. $388.9M for the prior year 17-week fiscal period ended May 29, 2021.

06:45 EDT Moderna announces amended COVID-19 supply agreement with EC - Moderna announced an agreement with the European Commission, or EC, to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product or updated booster vaccine candidate. The amendment allows participating Member States to have Moderna COVID-19 vaccine booster doses scheduled for delivery in the second quarter of 2022 to be delivered later in calendar year 2022 or early calendar year 2023. Participating Member States will have the possibility to receive the expected updated bivalent booster candidate following approval by the European Medicines Agency. Moderna's bivalent prototype and Omicron booster vaccine candidate is currently being evaluated in a Phase 2/3 study. The company expects initial data on mRNA-1273.214 in June to inform selection of its candidate for the Northern Hemisphere fall 2022 booster. Moderna continues to expect advanced purchase agreements of approximately $21 billion for 2022 and continues to believe that COVID market dynamics will result in sales slightly higher in the second half of 2022 than in the first half.

06:37 EDT ChromaDex partners with Juvenis for sales of Tru Niagen in South Korea - ChromaDex has partnered with Juvenis to conduct cross-border sales of Tru Niagen in South Korea. Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and dietary supplement industries. Tru Niagen will be available for sale in the South Korean market on several cross-border marketplaces.

06:36 EDT Warner Bros. Pictures Group names De Luca, Abdy co-chairpersons, CEOs - Former MGM film executives Michael De Luca and Pam Abdy have been appointed co-chairpersons and CEOs of Warner Bros. Pictures Group (WBD), which currently includes Warner Bros. Pictures, New Line Cinema, DC-Based Film Production, and Warner Bros. Feature Animation. As part of a new long-range strategy, Warner Bros. Pictures Group will be broken out into three distinct business segments with Warner Bros. Pictures/New Line Cinema, Warner Bros. Feature Animation, and DC-Based Film Production each under separate leadership. In the interim, these segments will remain under the film group with day-to-day oversight by De Luca and Abdy. Most recently, De Luca and Abdy led MGM Studios as motion picture group chairman and president, respectively, since 2020. They are stepping down following Amazon's (AMZN) $8.5B deal to acquire MGM and will join Warner Bros. Discovery this summer after a period of transition. De Luca and Abdy follow longtime studio executive Toby Emmerich who is stepping down as chairman of Warner Bros. Pictures Group.

06:32 EDT Centessa discontinues clinical development of lixivaptan in ADPKD - Centessa has made the strategic decision to discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease - ADPKD - including both the Phase 3 ACTION Study and the open-label ALERT Study. The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD, and the incremental development challenges and associated costs, following a recent observation of alanine aminotransferase and aspartate aminotransferase elevations in one subject in the ALERT Study. The company believes that lixivaptan is unlikely to achieve the differentiated safety and tolerability profile Centessa required for further development of the program. Discontinuation of lixivaptan development is expected to significantly reduce cash burn and extend cash runway into 2026.

06:12 EDT NASA selects Axiom, Collins Aerospace for space suit contract - NASA has selected Axiom Space (AXIM) and Collins Aerospace (RTX) to advance spacewalking capabilities in low-Earth orbit and at the Moon, by buying services that provide astronauts with next generation spacesuit and spacewalk systems to work outside the International Space Station, explore the lunar surface on Artemis missions, and prepare for human missions to Mars. "With these awards, NASA and our partners will develop advanced, reliable spacesuits that allow humans to explore the cosmos unlike ever before," said Vanessa Wyche, director of NASA's Johnson Space Center in Houston. "By partnering with industry, we are efficiently advancing the necessary technology to keep Americans on a path of successful discovery on the International Space Station and as we set our sights on exploring the lunar surface." Reference Link

06:04 EDT Cedar Fair reports record Memorial Day weekend revenues - Cedar Fair reported that preliminary year-to-date net revenues through Monday, May 30 increased 21%, or $60M, to a record $343M when compared with the five-month period ended Monday, June 3, 2019. Results for the five months ended May 30 are not directly comparable to the first five months of the last two years given the material impact of the coronavirus pandemic. The year-over-year increase in revenues was driven by a 28%, or $12.93, increase in in-park per capita spending to a record $59.70; and a 13%, or $5M, increase in out-of-park revenues to $45M. These favorable results were offset in part by a 210,000-visit decrease in attendance to 5.2 million guests, primarily the result of 14 fewer operating days in the current five-month period and the continued disruption within the group sales attendance channel. The fiscal five-month period through Memorial Day weekend traditionally represents approximately 20% of the company's full-year operating days. CEO Richard A. Zimmerman said, "...Through the Memorial Day weekend, general demand and season pass attendance remain ahead of 2019 levels. Meanwhile, we are seeing gradual improvement in demand trends in group sales as that attendance channel continues to recover from the disruption of the pandemic. We are also very encouraged by the continued strength of our long-lead indicators, including sales of all-season products and advanced bookings at our resort properties".

05:10 EDT Zealand Pharma appoints David Kendall as chief medical officer - Zealand Pharma announced the appointment of David Kendall as chief medical officer. Kendall most recently served as senior global medical advisor at Zealand and has more than 35 years of experience in diabetes and metabolic disease, with a broad-based career in research, education, clinical care and the pharmaceutical industry.